Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a significant drop in short interest in the month of September. As of September 15th, there was short interest totaling 5,259 shares, a drop of 77.7% from the August 31st total of 23,626 shares. Based on an average trading volume of 37,337 shares, the short-interest ratio is currently 0.1 days. Approximately 0.2% of the company’s stock are sold short.

Cardio Diagnostics Stock Up 2.1%

Shares of NASDAQ:CDIO traded up $0.04 during midday trading on Friday, reaching $1.95. The company had a trading volume of 38,594 shares, compared to its average volume of 31,766. Cardio Diagnostics has a 1-year low of $0.97 and a 1-year high of $7.91. The stock has a market cap of $5.77 million, a PE ratio of -0.67 and a beta of 2.28. The business’s 50 day moving average price is $1.86 and its 200 day moving average price is $1.99.

Cardio Diagnostics (NASDAQ:CDIO) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.51) EPS for the quarter. The company had revenue of $0.01 million for the quarter. Cardio Diagnostics had a negative net margin of 43,133.33% and a negative return on equity of 82.28%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cardio Diagnostics in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cardio Diagnostics presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Cardio Diagnostics

An institutional investor recently bought a new position in Cardio Diagnostics stock. Renaissance Technologies LLC bought a new position in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 15,348 shares of the company’s stock, valued at approximately $30,000. Renaissance Technologies LLC owned about 0.52% of Cardio Diagnostics at the end of the most recent quarter. Institutional investors own 8.06% of the company’s stock.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc is a biotechnology and medical technology company focused on the prevention and early detection of cardiovascular disease. The company combines artificial intelligence with genetic and epigenetic data to develop personalized tools intended to help identify cardiovascular risk and support more targeted care.

Its products include Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease, and PrecisionCHD, which is intended to help identify the presence of coronary heart disease.